KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Total Liabilities (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Total Liabilities for 17 consecutive years, with $3.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 11.74% to $3.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 billion, a 11.74% increase, with the full-year FY2025 number at $3.1 billion, up 11.74% from a year prior.
  • Total Liabilities was $3.1 billion for Q4 2025 at Bio-Rad Laboratories, up from $3.0 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $4.6 billion in Q3 2021 to a low of -$8.4 billion in Q2 2023.
  • A 5-year average of $2.9 billion and a median of $3.5 billion in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 326.03% in 2023, then soared 134.45% in 2024.
  • Bio-Rad Laboratories' Total Liabilities stood at $4.1 billion in 2021, then decreased by 5.41% to $3.9 billion in 2022, then decreased by 8.45% to $3.6 billion in 2023, then decreased by 21.45% to $2.8 billion in 2024, then rose by 11.74% to $3.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Total Liabilities are $3.1 billion (Q4 2025), $3.0 billion (Q3 2025), and $3.1 billion (Q2 2025).